Зорекс

General characteristics. Structure:

Capsules, 150 mg +7 mg 1 капс.
Active agents: dimercaptopro-pan-sodium sulphonate monohydrate (Unithiolum) of 150 mg, calcium pantothenate of 7 mg

Excipients: MKTs — 113,5 mg; citric acid monohydrate — 9,1 mg; starch prezhelatinizirovanny — 29,3 mg; hydrophosphate magnesium trihydrate — 30 mg; povidone — 6,1 mg; silicon dioxide colloid (aerosil) — 5 mg  

Gelatinous solid capsule: gelatin; titanium dioxide (E171); dye azoruby (E122) 
 
Capsules, 250 mg +10 mg 1 капс.
Active agents: dimercaptopro-pan-sodium sulphonate monohydrate (Unithiolum) of 250 mg, calcium pantothenate of 10 mg

Excipients: MKTs — 120,2 mg; citric acid monohydrate — 12,2 mg; starch prezhelatinizirovanny — 40,2 mg; hydrophosphate magnesium trihydrate — 50 mg; povidone — 9,4 mg; silicon dioxide colloid (aerosil) — 8 mg  
 
Gelatinous solid capsule: gelatin; titanium dioxide (E171); dye azoruby (E122).

Pharmacological properties:

Complexing drug. Donator of sulphhydryl (thiol) groups. Renders disintoxication (including in relation to ethanol half-decay products, heavy metals and their connections, arsenous connections) action. In clinical trials hepatoprotective and antioxidant action of Unithiolum is shown.
Active sulphhydryl groups of Unithiolum, interacting with the thiol poisons and products of half-decay of alcohol (ethanol) which are in blood and fabrics form with them non-toxic connections (complexes) which are removed with urine.
At administration of drug inside Unithiolum with a portal blood-groove gets into a liver where quickly and it is physiologically irreversible contacts acetic aldehyde that causes the subsequent removal of alcohol from other bodies and fabrics. Зорекс® activates also alcohol dehydrogenase, strengthening process of oxidation of ethanol and desintoxication of his toxic agents fermental system of a liver.
Existence in composition of the drug Zoreks® of calcium of pantothenate strengthens disintoxication action of Unithiolum. Calcium pantothenate is well soaked up from intestines and split, releasing pantothenic acid which participates in carbohydrate and a lipometabolism, stimulates formation of corticosteroids, accelerates regeneration processes.

Pharmacokinetics. Absorption. After intake of the capsule containing 250 mg of Unithiolum, Cmax of the last in blood is reached in 1.5 h and makes 90-140 mg/l. The average time of finding of drug in an organism - 9-11 h (10.16±0.39 h), including in a GIT - 15-20 min.
Calcium pantothenate is well soaked up from intestines and split, releasing pantothenic acid.

Removal. T1/2 makes 7.5±0.46 h.
About 60% of drug are removed with urine, partially - with a stake.

Indications to use:

— an alcoholic abstinence syndrome (for prevention and treatment of a hangover);
— an alcoholism (as a part of complex therapy);
— acute and chronic poisonings with organic and inorganic compounds of arsenic, mercury, gold, chrome, cadmium, cobalt, copper, zinc, nickel, bismuth, antimony, intoxication with cardiac glycosides.

Route of administration and doses:

Inside, in 30 min. prior to food, without chewing, washing down with water.

Prevention of a hangover: after alcohol intake 1 капс. (250 mg +10 mg) in the evening before going to bed.

Treatment of an alcoholic abstinence syndrome: on 1 капс. (250 mg +10 mg) 1–2 times a day. If necessary it is possible to increase a daily dose to 750 mg (on dimercaptopro-pan-sodium sulphonate), and to finish frequency rate of reception to 3 times a day. It is necessary to accept drug 3–7 days, before the termination of symptoms of intoxication.

At alcoholism: on 1 капс. (150 mg +7 mg) 1–2 times a day, within 10 days.

At poisonings with compounds of arsenic and salts of heavy metals: 300–1000 mg/days (on dimercaptopro-pan-sodium sulphonate) for 2–3 receptions, within 7–10 days.

Features of use:

Influence on ability to driving of motor transport and to control of mechanisms
Drug does not influence performance of potentially dangerous types of activity requiring special attention and bystry reactions (driving and other vehicles, work with moving mechanisms, work of the dispatcher and operator, etc.).

Side effects:

Allergic reactions: seldom - the skin itch, a small tortoiseshell, rash on skin and mucous, swelled mucous, a genital itch, stomatitis; very seldom - emergence of allergic reaction as a Quincke's disease or Stephen-Johnson's syndrome (sudden fervescence, an indisposition, a spotty and vesicular or violent enanthesis, mucous membranes of an oral cavity, generative organs, in the field of an anus). In this case it is necessary to stop administration of drug and to see a doctor. The risk of development of allergic reactions is higher at persons with bronchial asthma or existence of an allergy in the anamnesis.

At use in high doses: nausea, dizziness, tachycardia, pallor of integuments.

Interaction with other medicines:

It is not compatible to the medicines containing salts of heavy metals and also to alkalis (quickly decays).

Contraindications:

— a serious illness of a liver in a decompensation stage;
— a serious illness of kidneys in a decompensation stage;
— children's age up to 18 years;
— hypersensitivity to drug components.

With care it is necessary to use drug at the lowered ABP.

Use of the drug ZOREKS® at pregnancy and feeding by a breast
There are no data on use of the drug Zoreks® at pregnancy and in the period of a lactation (breastfeeding). Due to the lack of necessary data use at pregnancy and during breastfeeding is contraindicated.

Use at abnormal liver functions
Drug is contraindicated at a serious illness of a liver in a decompensation stage.

Use at renal failures
Drug is contraindicated at a serious illness of kidneys in a decompensation stage.

Use for children
It is contraindicated to children aged up to 18 years.

Overdose:

Symptoms of overdose can appear at exceeding of the recommended dose more than by 10 times.
Symptoms: asthma, hyperkinesias, block, slackness, oglushennost, short-term spasms.

Treatment: gastric lavage, purpose of absorbent carbon, laxative drugs. Carry out symptomatic therapy, in acute cases the oxygenotherapy, introduction of a dextrose is shown.

Storage conditions:

Drug should be stored in the unavailable to children, dry, protected from light and moisture place at a temperature not above 25 °C.

Issue conditions:

Without recipe

Packaging:

Capsules, 150 mg +7 mg or 250 mg +10 mg. In a blister strip packaging from the film of PVC and printing aluminum foil varnished on 2, 5 pieces (250 mg +10 mg) or 10 pieces (150 mg +7 mg). 1 blister strip packaging on 10 pieces (150 mg +7 mg), 1 blister strip packaging on 2 pieces (250 mg +10 mg) or 2 blister strip packagings on 5 pieces (250 mg +10 mg) in a pack from a cardboard.